Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells
出版年份 2017 全文链接
标题
Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells
作者
关键词
Cancer stem cells, Breast cancer, Hyperexpression techniques, Cancer treatment, Cancer chemotherapy, Vimentin, Cytoskeletal proteins, Stem cell lines
出版物
PLoS One
Volume 12, Issue 8, Pages e0183578
出版商
Public Library of Science (PLoS)
发表日期
2017-08-18
DOI
10.1371/journal.pone.0183578
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- EMT, CTCs and CSCs in tumor relapse and drug-resistance
- (2015) Abhisek Mitra et al. Oncotarget
- Tumor-Initiating Cells and FZD8 Play a Major Role in Drug Resistance in Triple-Negative Breast Cancer
- (2013) S. Yin et al. MOLECULAR CANCER THERAPEUTICS
- Disparities in Breast Cancer Treatment and Outcomes: Biological, Social, and Health System Determinants and Opportunities for Research
- (2013) S. B. Wheeler et al. ONCOLOGIST
- Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin
- (2013) Juan Manuel Iglesias et al. PLoS One
- Cadherins in collective cell migration of mesenchymal cells
- (2012) Eric Theveneau et al. CURRENT OPINION IN CELL BIOLOGY
- Early events in cell adhesion and polarity during epithelial-mesenchymal transition
- (2012) R. Y.-J. Huang et al. JOURNAL OF CELL SCIENCE
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
- (2012) Dai Horiuchi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Triple-negative breast cancers: an updated review on treatment options
- (2011) K. B. Reddy Current Oncology
- Heterogeneity in breast cancer
- (2011) Kornelia Polyak JOURNAL OF CLINICAL INVESTIGATION
- MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors
- (2011) Aatur D Singhi et al. MODERN PATHOLOGY
- Wnt Proteins Are Self-Renewal Factors for Mammary Stem Cells and Promote Their Long-Term Expansion in Culture
- (2010) Yi Arial Zeng et al. Cell Stem Cell
- Targeting Breast Cancer Stem Cells
- (2010) Suling Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1
- (2010) E Sánchez-Tilló et al. ONCOGENE
- Directed Therapy of Subtypes of Triple-Negative Breast Cancer
- (2010) L. A. Carey ONCOLOGIST
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
- (2010) D. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A pathway-based classification of human breast cancer
- (2010) M. L. Gatza et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EMT, the cytoskeleton, and cancer cell invasion
- (2009) Mahmut Yilmaz et al. CANCER AND METASTASIS REVIEWS
- Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
- (2009) Bin-Bing S. Zhou et al. NATURE REVIEWS DRUG DISCOVERY
- Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup
- (2009) M. Chehani Alles et al. PLoS One
- A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response
- (2009) Sanjay Chandriani et al. PLoS One
- Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
- (2009) J. J. Molenaar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Why Myc? An Unexpected Ingredient in the Stem Cell Cocktail
- (2008) Paul S. Knoepfler Cell Stem Cell
- c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells
- (2008) Jialiang Wang et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation